文献速递慢性肾脏病水电解质与酸碱

维生素D在CKD 3至4期中的作用:国家肾脏基金会科学研讨会报告

The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
PubMed 文献 · Am J Kidney Dis · 2018-10-05

该报告由国家肾脏基金会赞助的争议性会议产生,三个工作组讨论了CKD 3-4期维生素D缺乏的评估与管理。专家组建议将25(OH)D>20ng/mL且无counter-regulatory激素活性证据视为充足,<15ng/mL应治疗,15-20ng/mL无证据时可不治疗。建议先补充营养性维生素D再使用活性维生素D化合物,并呼吁进一步研究重要结局。

要点

  • 25(OH)D>20ng/mL且无PTH升高视为充足,<15ng/mL应治疗。
  • 15-20ng/mL且无counter-regulatory激素活性证据可能不需治疗。
  • 先补充营养性维生素D(胆钙化醇、麦角钙化醇或calcifediol)再使用活性维生素D。

核心结论

  • CKD 3-4期患者25(OH)D缺乏常见且与不良结局相关,但评估和管理仍存争议。
  • 专家组就25(OH)D分类和治疗阈值达成共识,并建议优先补充营养性维生素D。

研究设计与样本

  • 国家肾脏基金会赞助的争议性会议,三个工作组参与讨论并形成报告。

主要发现

  • 25(OH)D缺乏在CKD 3-4期患者中常见,并与不良结局相关。
  • 专家组一致认为25(OH)D>20ng/mL且无counter-regulatory激素活性证据为充足。
  • 25(OH)D<15ng/mL应治疗,不考虑PTH水平。
  • 25(OH)D 15-20ng/mL且无counter-regulatory激素活性证据可能不需治疗。

关键数值与推荐

  • 25(OH)D充足:>20ng/mL且无counter-regulatory激素活性证据(如PTH升高)。
  • 25(OH)D<15ng/mL:应治疗,不考虑PTH水平。
  • 25(OH)D 15-20ng/mL:无counter-regulatory激素活性证据时可能不需治疗。
  • 补充顺序:先使用营养性维生素D(胆钙化醇、麦角钙化醇或calcifediol),再使用活性维生素D化合物。

临床怎么用

  • 临床应根据25(OH)D水平和counter-regulatory激素活性证据分类管理CKD 3-4期患者。
  • 对25(OH)D<15ng/mL的患者应治疗,无需等待PTH结果。
  • 优先选用营养性维生素D补充,再考虑活性维生素D化合物。

局限性

  • 需要进一步研究评估与低25(OH)D相关的重要结局,如进展至终末期肾病、感染、骨折率、住院和全因死亡率。
  • 呼吁增加该领域的研究资金。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deficiency of 25-hydroxyvitamin D (25[OH]D) is common in patients with chronic kidney disease stages 3 and 4 and is associated with poor outcomes. However, the evaluation and management of vitamin D deficiency in nephrology remains controversial. This article reports on the proceedings from a "controversies conference" on vitamin D in chronic kidney disease that was sponsored by the National Kidney Foundation. The report outlines the deliberations of the 3 work groups that participated in the conference. Until newer measurement methods are widely used, the panel agreed that clinicians should classify 25(OH)D "adequacy" as concentrations > 20ng/mL without evidence of counter-regulatory hormone activity (ie, elevated parathyroid hormone). The panel also agreed that 25(OH)D concentrations < 15ng/mL should be treated irrespective of parathyroid hormone level. Patients with 25(OH)D concentrations between 15 and 20ng/mL may not require treatment if there is no evidence of counter-regulatory hormone activity. The panel agreed that nutritional vitamin D (cholecalciferol, ergocalciferol, or calcifediol) should be supplemented before giving activated vitamin D compounds. The compounds need further study evaluating important outcomes that observational studies have linked to low 25(OH)D levels, such as progression to end-stage kidney disease, infections, fracture rates, hospitalizations, and all-cause mortality. We urge further research funding in this field.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Melamed ML, Chonchol M, Gutiérrez OM, et al. The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2018. PMID: 30297082. doi:10.1053/j.ajkd.2018.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。